Amgen - denosumab: meh!

An FDA advisory panel recommended that the agency approve Amgen's denosumab to treat certain patients with osteoporosis, but did not support approval for the drug as a preventive measure against bone loss in low-risk patients, Amgen reported on Thursday. Advisory committee member Clifford Rosen remarked that "we still don't have enough data at three years out that we can advocate for a preventive indication." Full story